Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool March 21, 2005 Alyce Lomax	Stock Madness 2005: Dell vs. Celgene The computer maker and the biotech company vie for a berth in the next round of "Stock Madness 2005," a contest based loosely on the annual NCAA College Basketball Tournament, a.k.a. March Madness.
The Motley Fool March 30, 2005 Charly Travers	Stock Madness 2005: Celgene vs. Netflix Biotech battles entertainment in this Round 3 matchup of "Stock Madness 2005," a contest based loosely on the annual NCAA College Basketball Tournament, a.k.a. March Madness.
The Motley Fool March 22, 2005 Travers & Djuranovic	Stock Madness 2005: Protein Design Labs vs. Taser One keeps you healthy; the other keeps you safe. But which one will make your portfolio happier? "Stock Madness 2005," a contest based loosely on the annual NCAA College Basketball Tournament, a.k.a. March Madness shows the way.
The Motley Fool March 22, 2006 Tim Hanson	Stock Madness 2006: Rage Against the Hype Machine Solid returns from solid companies are highlighted in this investing series based loosely on the annual NCAA College Basketball Tournament, a.k.a. "March Madness." Berkshire Hathaway... Valero... American Financial... etc.
The Motley Fool March 30, 2005 Travers & Smith	Stock Madness 2005: Protein Design Labs vs. Plum Creek Timber This biotech isn't as risky as you might think. But is it as solid as a tree company? Find out in "Stock Madness 2005," a contest based loosely on the annual NCAA College Basketball Tournament, a.k.a. March Madness.
The Motley Fool March 28, 2005 Charly Travers	Stock Madness 2005: Protein Design Labs vs. Yahoo! Two very different Rule Breakers face off in "Stock Madness 2005," a contest based loosely on the annual NCAA College Basketball Tournament, a.k.a. March Madness.
The Motley Fool March 22, 2006 Charly Travers	Stock Madness 2006: The Biotech Dream Team The rewards can cancel out the risks, and then some. Investors, who wins this round of the investing series based loosely on the annual NCAA College Basketball Tournament, a.k.a. "March Madness?" Amgen... Foxhollow Technologies... etc.
The Motley Fool March 22, 2005 Djuranovic & Hwang	Stocks 2005: Silicon Labs vs. Home Depot Who'll win this cross-industry match-up? Join "Stock Madness 2005," a contest based loosely on the annual NCAA College Basketball Tournament, a.k.a. March Madness to find out.
The Motley Fool March 31, 2006 Tim Hanson	Stock Madness Finals: The Power of a Micro Cap This team of value-priced companies has one breakout star in this year's investing game based loosely on the annual NCAA College Basketball Tournament, a.k.a. Mach Madness. Berkshire Hathaway... Valero... National Research... etc.
The Motley Fool November 24, 2006 Philip Durell	The Best International Stock for 2007: Lloyds TSB Lloyds is focused in the U.K., which gives U.S. investors a hedge against further declines in the dollar. Also, the company is still undervalued and has opportunities to create more value for shareholders.
The Motley Fool February 6, 2007 Brian Lawler	Celgene Mints the Green Stuff Biotech firm Celgene reports its 2006 financial results and provides an update for its 2007 guidance. Biopharma investors know it's not the past that matters the most in this sector; it's the outlook.
The Motley Fool May 8, 2007 Brian Lawler	Unstoppable Celgene The biotech powerhouse continues its strong financial results as Revlimid sales grow.
The Motley Fool June 8, 2010 Rich Smith	This Just In: Upgrades and Downgrades Is Celgene the new Genentech? Maybe not -- but it's cheap.
The Motley Fool November 20, 2007 Brian Orelli	Celgene Buys a Sales Force Pharmaceutical Celgene acquires Pharmion for $2.9 billion, hoping that Pharmion's two drugs in mid-to-late clinical trials will justify the purchase price in the not-too-distant future.
The Motley Fool July 14, 2005 Stephen D. Simpson	Dueling Fools: Protein Design Labs Bear Protein Design Labs could be a big winner, or a major loser. The biotech has a strong business, but today's stock price isn't "great."
The Motley Fool December 31, 2007 Todd Wenning	Best Stock for 2008: Lloyds TSB A bank that's actually worth buying. Lloyds TSB is a U.K.-based retail bank that actually generates most of its revenue from its life insurance and pension/investment wing. Investors, take note.
The Motley Fool January 13, 2009 Brian Orelli	Celgene's Still Surging With returns over the last five years that just about any investor would love to have, it might be fair to wonder whether Celgene can keep it up. It seems it can.
The Motley Fool August 28, 2006 Brian Lawler	The Commandments of Biotech Investing Since long-term successful biotech investing requires accurate risk assessment, you must be aware of the risk you're taking on. Just as with any prospective investment, if you diversify your biotech holdings, you can somewhat mitigate these various risks.
The Motley Fool January 29, 2010 Brian Orelli	Wake Up! You Still Have to Pay Attention We already knew Celgene's preliminary numbers, but the conference call offers a look ahead.
The Motley Fool April 26, 2006 Tim Beyers	Where the Yields Are The best dividend payers are perhaps not where you think. Great businesses that boast high yields can be found in any industry, as long as you broaden your search to overseas markets.
The Motley Fool April 28, 2011 Brian Orelli	Celgene Gets No Love The market shrugs off a solid quarter.
The Motley Fool January 11, 2010 Brian Orelli	Celgene Revs Up for a New Year Preliminary 2009 sales released at the J.P. Morgan Health Care Conference have sales up about 20% year over year and Celgene is guiding for 20% revenue growth next year as well.
The Motley Fool July 24, 2009 Brian Orelli	Juicing Up the Earnings Report How did Celgene turn an earnings release that met analysts' expectations while lowering revenue guidance on one of its drugs into an 18.6% increase in share price yesterday?
The Motley Fool April 30, 2010 Brian Orelli	New CEO, Same Old Double-Digit Increases Another strong quarter from Celgene.
The Motley Fool April 4, 2005 John Reeves	Returns That Defy the Imagination Want to save lives while pursuing a high-growth investment strategy? Try exploring the biotech frontier.
The Motley Fool April 4, 2009 Brian Orelli	The Wrong Way to Invest in the Right Stocks Exchange-traded funds don't work for this industry.
The Motley Fool May 5, 2009 Brian Orelli	The Wrong Way to Invest in the Right Stocks Persuading you to invest in biotechs should be easy. Persuading you not to use what seems like a less-risky strategy might be harder. Exchange-traded funds just don't work for this industry.
The Motley Fool October 30, 2006 Brian Lawler	Celgene: Drug Kingpin Trading at 129 times trailing-12-month adjusted earnings, the biopharmaceutical looks ridiculously expensive, until one considers its awesome sales and earnings growth in that time period. Investors, take note.
Chemistry World July 29, 2015 Phillip Broadwith	Celgene to buy immune-inflammatory specialist Receptos The deal gives Celgene access to Receptos's pipeline of inflammation and immunology treatments.
The Motley Fool December 8, 2010 Brian Orelli	Winners and Losers at the Hematology Society Meeting The American Society of Hematology annual meeting wrapped up yesterday, and as with pretty much every medical meeting, we've got some winning and losing blood-cancer drugs.
The Motley Fool December 30, 2004 Paul Elliott	Why Daddy Loves This Stock Investing a friend's hard-earned money can be every bit as unnerving as investing your own. Let's take a look at Protein Design Labs, the leader in antibody humanization technology.
The Motley Fool November 4, 2011 Luke Timmerman	Celgene to Pump $45M Into Quanticel to Discover Cancer Drugs Celgene strikes an unusual agreement.
The Motley Fool May 17, 2006 Shannon Zimmerman	Cheap Stocks! Free Money! It can pay to buy dividends at a discount. Investors, check out Lloyds TSB Group, the British-based banking concern.
The Motley Fool February 16, 2007 Brian Lawler	The Biotech Academy Awards Investors, here are some biotech Oscars for last year's performances: The Biotech Best Picture award -- Celgene... The Biotech Best Drama -- Elan and BiogenIdec... etc.
The Motley Fool January 31, 2008 Brian Lawler	Prioritizing Millennium The FDA grants a speedy review for Millennium Pharmaceuticals's lead multiple myeloma drug.
The Motley Fool June 9, 2010 Brian Orelli	ASCO Pops and Drops Themes and company news from the annual meeting of the American Society of Clinical Oncology.
The Motley Fool August 9, 2006 Stephen D. Simpson	Lloyds: Good News and Bad With a high dividend and the possibility that the worst may be behind the British banking industry, Lloyds could be a reasonable idea for patient investors.
The Motley Fool October 6, 2010 Brian Orelli	Celgene Is All Grown Up An acquirer is on the prowl.
The Motley Fool July 29, 2005 W.D. Crotty	A High-Yield Intrinsic Value Play Lloyds is reporting solid growth and executing its plan. And, since the stock is up only 7.4% since its recommendation, the astute investor may be able to pick up shares at a discount.
The Motley Fool January 28, 2011 Brian Orelli	Celgene Needs a Rocket Ship Celgene really needs a hit from Abraxane and other drugs it may license or purchase.
The Motley Fool July 29, 2010 Brian Orelli	This Best Biotech Is Cheaper Than You Think The cancer-drug specialist justifies its valuation quite effectively with a stellar second-quarter performance.
The Motley Fool October 11, 2011 Arlene Weintraub	Agios and Celgene: Anatomy of an Ultra-Valuable Biotech Marriage An unprecedented cancer drug development deal.
The Motley Fool July 13, 2005 Chuck Saletta	How to Buy Low and Sell High Use Ben Graham's margin of safety to buy and sell stocks profitably.
The Motley Fool March 13, 2006 Rick Aristotle Munarriz	Where Will You Be Tomorrow? Your stocks are set for the future. Now it's your turn.
The Motley Fool February 1, 2006 Vitaliy Katsenelson	Lloyds: Prime for Takeover Rumors surface of a Lloyds takeover by Spanish bank BBVA. Investors, take note.
BusinessWeek June 13, 2005 Arlene Weintraub	Why Biotech Stocks Are Sedated Biotech might seem like a can't-miss investing opportunity but many investors are taking a pass on biotech, even amid bona fide scientific advances.
The Motley Fool June 14, 2007 Tim Beyers	Who's Buying Now? Sometimes, insiders are buying for all the right reasons. Who's at it this week? Celgene... Chesapeake Energy... Einstein Noah Restaurant Group... Kinder Morgan Management... Osiris Therapeutics... etc.
The Motley Fool January 30, 2009 Brian Orelli	Celgene's Double Take Still Looks Good No one is going to stop using Celgene's cancer-fighting products just because the economy is in the tank, so the company should have no problem hitting or even exceeding its growth estimates the way it has before.
The Motley Fool September 24, 2007 Brian Lawler	An Array of Good News Small pharmaceutical firm Array BioPharma signs a big partnership deal with Celgene. Investors, take note.
The Motley Fool December 14, 2006 Brian Lawler	Celgene Faces a Generic Challenge An abbreviated application is only an opening salvo in Barr's challenge to Celgene's Thalomid patents. Investors, take note.